文献速递浆细胞疾病

靶向LAG3/GAL-3克服多发性骨髓瘤免疫抑制并增强抗肿瘤免疫应答

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma.
PubMed 文献 · Leukemia · 2021-07-21

该研究对比MGUS/SMM与MM患者的免疫特征,发现MM患者CD4+ Th细胞减少、Treg与G型MDSC增多且免疫检查点上调,LAG3在增殖的CD4+ Th和CD8+ Tc细胞上表达最高。抗LAG3抗体可增强T细胞增殖与抗MM活性,抗GAL-3处理亦增强MM特异性应答。研究提示阻断LAG3/GAL-3单用或联合多肽疫苗可增强抗肿瘤反应。

要点

  • MM患者LAG3在增殖的CD4+ Th和CD8+ Tc细胞上高表达。
  • 抗LAG3可增强T细胞增殖及针对MM的活性。
  • 抗LAG3或抗GAL-3可增强MM特异性应答,联合疫苗策略有前景。

核心结论

  • 阻断LAG3/GAL-3单用或联合XBP1/CD138/CS1多肽疫苗可增强MM抗肿瘤应答并改善患者结局。

研究设计与样本

  • 对比MGUS/SMM患者与MM患者及健康个体的免疫特征,并在体外评估抗LAG3和抗GAL-3处理对T细胞及抗原特异性CTL的影响。

主要发现

  • MM患者较MGUS/SMM或健康个体CD4+ Th细胞减少、Treg与G型MDSC增多,效应/调节细胞及CD138+细胞上免疫检查点上调。
  • LAG3在MM患者BMMC和PBMC中增殖的CD4+ Th和CD8+ Tc细胞上表达最高。
  • 抗LAG3处理显著增强T细胞增殖及抗MM活性,并进一步增强体外生成的XBP1/CD138/CS1特异性CTL的抗MM活性。
  • Treg和G型MDSC弱表达LAG3,受抗LAG3影响最小。
  • CD138+ MM细胞表达LAG3配体GAL-3,抗GAL-3处理增加MM特异性应答;检查点抑制剂治疗可诱发非靶向检查点上调导致耐药。

临床怎么用

  • 可考虑将LAG3/GAL-3阻断作为MM免疫治疗策略,尤其与XBP1/CD138/CS1多肽疫苗联合。
  • 需关注检查点抑制剂治疗中非靶向检查点上调导致的耐药,并探索联合方案克服耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune profiling in patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM) provides the framework for developing novel immunotherapeutic strategies. Here, we demonstrate decreased CD4+ Th cells, increased Treg and G-type MDSC, and upregulation of immune checkpoints on effector/regulatory and CD138+ cells in MM patients, compared MGUS/SMM patients or healthy individuals. Among the checkpoints profiled, LAG3 was most highly expressed on proliferating CD4+ Th and CD8+ Tc cells in MM patients BMMC and PBMC. Treatment with antibody targeting LAG3 significantly enhanced T cells proliferation and activities against MM. XBP1/CD138/CS1-specific CTL generated in vitro displayed anti-MM activity, which was further enhanced following anti-LAG3 treatment, within the antigen-specific memory T cells. Treg and G-type MDSC weakly express LAG3 and were minimally impacted by anti-LAG3. CD138+ MM cells express GAL-3, a ligand for LAG3, and anti-GAL-3 treatment increased MM-specific responses, as observed for anti-LAG3. Finally, we demonstrate checkpoint inhibitor treatment evokes non-targeted checkpoints as a cause of resistance and propose combination therapeutic strategies to overcome this resistance. These studies identify and validate blockade of LAG3/GAL-3, alone or in combination with immune strategies including XBP1/CD138/CS1 multipeptide vaccination, to enhance anti-tumor responses and improve patient outcome in MM.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Bae J, Accardi F, Hideshima T, et al. Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. Leukemia. 2021. PMID: 34290359. doi:10.1038/s41375-021-01301-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。